| 刘新红,晁芳芳,傅萍,叶茂.丹参酮ⅡA磺酸钠注射液联合美沙拉嗪肠溶片治疗溃疡性结肠炎的临床研究[J].实用中西医结合临床,2022,22(9): |
| 丹参酮ⅡA磺酸钠注射液联合美沙拉嗪肠溶片治疗溃疡性结肠炎的临床研究 |
| Clinical study of sodium tanshinone Ⅱ a sulfonate injection combined with mesalazine enteric coated tablets in the treatment of ulcerative colitis |
| 投稿时间：2022-04-18 修订日期：2022-05-05 |
| DOI： |
| 中文关键词: 丹参酮ⅡA磺酸钠注射液 美沙拉嗪肠溶片 临床疗效 C反应蛋白 粪便钙卫蛋白 凝血功能 不良反应 |
| 英文关键词: Tanshinone Ⅱ a sodium sulfonate injection Mesalazine enteric coated tablets Clinical efficacy C-reactive protein Coagulation function Adverse reaction |
| 基金项目: |
|
| 摘要点击次数: 434 |
| 全文下载次数: 107 |
| 中文摘要: |
| 目的：分析丹参酮ⅡA磺酸钠注射液联合美沙拉嗪肠溶片在溃疡性结肠炎治疗中的作用。 方法：纳入溃疡性结肠炎患者60例,均为江西中医药大学附属医院消化科、肛肠科住院部收治患者,诊治时间为2021年1月至2021年12月,按照患者入院治疗先后顺序轮流交替分成对照组和观察组,30例为对照组,仅用美沙拉嗪肠溶片,观察组30例在对照组的基础上联合应用丹参酮ⅡA磺酸钠注射液,比较两组临床疗效、炎症指标(C反应蛋白、粪便钙卫蛋白)、凝血功能(血小板计数、血小板平均体积、活化部分凝血酶原时间、纤维蛋白原、D-二聚体)和药物不良反应。 结果：观察组总有效率为95.68%,明显高于对照组的72.32%,组间差异明显(P<0.05)；患者用药前,炎症指标(C反应蛋白、粪便钙卫蛋白)和凝血功能指标无差别(P>0.05),观察组治疗后C反应蛋白为(11.16±1.72)mg/L,血小板计数为(190.16±34.12)×109/L,粪便钙卫蛋白为(103.26±12.62)μg/g、纤维蛋白原为(3.98±0.27)g/L,D-二聚体为(0.24±0.04)mg/L,低于对照组的(17.21±2.14)mg/L、(212.42±32.56)×109/L、(122.21±14.14)μg/g 、(4.42±0.36)g/L、(0.48±0.06)mg/L,血小板平均体积和活化部分凝血酶原时间分别为(9.56±0.45)fl和(37.18±2.54)s,高于对照组的(8.21±0.44)fl和(33.92±2.16)s,两组各项指标逐一对比有差异(P<0.05)；两组药物不良反应对比无差异(P>0.05)。 结论：在溃疡性结肠炎患者的治疗中联合应用丹参酮ⅡA磺酸钠注射液和美沙拉嗪肠溶片,效果好,可减少C反应蛋白释放,粪便钙卫蛋白指数下降,炎症指标下降,对凝血功能有改善作用,不增加药物不良反应,有临床推广价值。 |
| 英文摘要: |
| Objective To analyze the effect of sodium tanshinone IIA sulfonate injection + mesalazine enteric coated tablets in the treatment of ulcerative colitis. Methods 60 patients with ulcerative colitis were admitted to the Department of Gastroenterology and anorectal inpatient department of the Affiliated Hospital of Jiangxi University of traditional Chinese medicine. The diagnosis and treatment time was from January 2021 to December 2021. They were treated equally according to the time of admission. 30 patients in the control group were treated with mesalazine enteric coated tablets only, and 30 patients in the observation group were treated with tanshinone IIA sodium sulfonate injection. The clinical effects of the two groups were compared Inflammatory factors, coagulation function and adverse drug reactions.Results The total effective rate in the observation group was 96.67%, which was significantly higher than 73.33% in the control group (P < 0.05); Before treatment, there was no difference in inflammatory factors and coagulation function indexes (P > 0.05). After treatment, C-reactive protein was (11.16 ± 1.72) mg / L and platelet count was (190.16 ± 34.12) in the observation group × 109 / L, fibrinogen (3.98 ± 0.27) g / L, D-Dimer (0.24 ± 0.04) mg / L, lower than (17.21 ± 2.14) mg / L and (212.42 ± 32.56) mg / L in the control group × 109 / L, (4.42 ± 0.36) g / L, (0.48 ± 0.06) mg / L, the average platelet volume and activated partial prothrombin time were (9.56 ± 0.45) FL and (37.18 ± 2.54) s, respectively, higher than those in the control group (8.21 ± 0.44) FL and (33.92 ± 2.16) s. there were differences in each index between the two groups (P < 0.05); There was no difference in adverse drug reactions between the two groups (P > 0.05). Conclusion In the treatment of patients with ulcerative colitis, the combined application of sodium tanshinone IIA sulfonate injection and mesalazine enteric coated tablets has good effect, can reduce the release of C-reactive protein, improve coagulation function, and do not increase adverse drug reactions. It has popularization value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
